Strength Seen in Intellia Therapeutics ( NTLA ) : Can Its 29.8% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
CG Oncology, Inc. ( CGON ) Moves 5.5% Higher: Will This Strength Last?
CG Oncology, Inc. (CGON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CG Oncology Stock Signals Bullish Momentum Ahead - CG Oncology ( NASDAQ:CGON )
CG Oncology CGON has moved into Phase 2 of its 18-phase Adhishthana cycle, a critical stage that often sets the tone for early bullish momentum. Within this phase, the stock transitions into what's called the Buddhi move period, where breakouts are more likely to unfold.
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months - CG Oncology ( NASDAQ:CGON )
- Robust 24-month complete response ( CR ) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer ( NMIBC ) who are unresponsive to Bacillus Calmette Guerin ( BCG ) treatment - - 90% of 12-month responders remained disease free at 24 ...
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
- Robust 24-month complete response ( CR ) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer ( NMIBC ) who are unresponsive to Bacillus Calmette Guerin ( BCG ) treatment -- 90% of 12-month responders remained disease free at 24 ...
CG Oncology Completes Enrollment in PIVOT-006
- Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer ( NMIBC ) -- One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per AUA/SUO Guidelines ...
CG Oncology's Executive Leadership to Participate in Upcoming Investor Conferences - CG Oncology ( NASDAQ:CGON )
IRVINE, Calif., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc.
CG Oncology's Executive Leadership to Participate in Upcoming Investor Conferences
IRVINE, Calif., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc. ( NASDAQ: CGON ) , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, ...
Cg Oncology ( CGON ) Q2 Loss Widens 93%
Cg Oncology ( NASDAQ:CGON ) , a clinical-stage biotechnology company focused on developing therapies for bladder cancer, reported its second quarter fiscal 2025 earnings on August 8, 2025. The company disclosed a net loss that was more than double that of the same quarter in 2024.
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting -
Arbutus Biopharma ( ABUS ) Beats Q2 Earnings and Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) , a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( TIL ) therapies for patients with cancer, today announced ...
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
Hong Kong healthcare investor looks for biotech's 'DeepSeek moment' in China
ORI Capital is planning a US$350 million fund to focus on Chinese biotech, with hopes that AI will help beat the market.
Company News for May 14, 2025
Companies in The News Are: ...
CG Oncology, Inc. ( CGON ) Reports Q1 Loss, Lags Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -15.38% and 90.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. ( YMAB ) Reports Q1 Loss, Tops Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of 45.45% and 6.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
CG Oncology, Inc. ( CGON ) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CG Oncology, Inc. ( CGON ) Surges 25.0%: Is This an Indication of Further Gains?
CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - CG Oncology ( NASDAQ:CGON ) , Galmed Pharmaceuticals ( NASDAQ:GLMD )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday. The Dow traded down 0.27% to 40,004.11 while the NASDAQ fell 1.19% to 17,175.43. The S&P 500 also fell, dropping, 0.72% to 5,485.36. Financial shares jumped by 0.6% on Monday.
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why - CG Oncology ( NASDAQ:CGON )
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG. 97.3% of patients in Cohort C remained free from muscle-invasive progression at 24 months; safety profile well tolerated. Feel unsure about the market's next move?
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday - ADMA Biologics ( NASDAQ:ADMA ) , Aurora Innovation ( NASDAQ:AUR )
U.S. stocks were mostly higher, with the Dow Jones index gaining around 200 points on Monday. Shares of CEMEX, S.A.B. de C.V. CX rose sharply during Monday's session following first-quarter results. The company reported first-quarter net sales of $3.65 million, missing the consensus of $3.80 ...
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings - CG Oncology ( NASDAQ:CGON ) , Domino's Pizza ( NASDAQ:DPZ )
U.S. stocks traded higher this morning, with the Dow Jones index more than 150 points on Monday. Following the market opening Monday, the Dow traded up 0.47% to 40,300.68 while the NASDAQ rose 0.13% to 17,405.94. The S&P 500 also rose, gaining, 0.31% to 5,542.29. Industrials shares jumped by ...
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at ...
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Korro Bio ( NASDAQ:KRRO ) , CG Oncology ( NASDAQ:CGON )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Wall Street Analysts Believe CG Oncology, Inc. ( CGON ) Could Rally 157.91%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Company News for Mar 31, 2025
Companies In The News Are: LULU, BRZE, AIR, CGON.
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
- Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve ( Cohort A ) and BCG-Exposed ( Cohort B ) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress -
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates - CG Oncology ( NASDAQ:CGON )
IRVINE, Calif., March 12, 2025 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc.
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug - ImmunityBio ( NASDAQ:IBRX )
HC Wainwright projects Anktiva sales to grow from $137.4 million in 2025 to $4.3 billion. ImmunityBio reported $7.21 million Q4 revenue, totaling $14.2 million in FY24. Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential. Get the latest picks today before ...
Is ANI Pharmaceuticals ( ANIP ) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.
Does CG Oncology, Inc. ( CGON ) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?
The consensus price target hints at a 123.3% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nasdaq Welcomed 171 IPOs in 2024
Leading U.S. exchange by number of IPOs and proceeds raised for the sixth consecutive year ...
Nasdaq Welcomed 171 IPOs in 2024 - Nasdaq ( NASDAQ:NDAQ )
NEW YORK, Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Nasdaq NDAQ announced today that in 2024, it welcomed 171 initial public offerings ( IPOs ) , raising a total of $22.7 billion.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - CG Oncology ( NASDAQ:CGON )
IRVINE, Calif., Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc.
CG Oncology Announces Pricing of Public Offering - CG Oncology ( NASDAQ:CGON )
IRVINE, Calif., Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc.
CG Oncology Announces Pricing of Public Offering
IRVINE, Calif., Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc. ( Nasdaq: CGON ) , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the ...
Why CG Oncology ( CGON ) Stock Is Down 9% - CG Oncology ( NASDAQ:CGON )
CG Oncology Inc CGON shares are trading lower by 6.02% to $31.67 during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock.
CG Oncology Announces Proposed Public Offering
IRVINE, Calif., Dec. 11, 2024 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc. ( Nasdaq: CGON ) , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that it ...
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer ( NMIBC ) Research Fellowship Award
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award ...
CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate - CG Oncology ( NASDAQ:CGON )
On Thursday, CG Oncology, Inc. CGON revealed topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer ( NMIBC ) unresponsive to Bacillus Calmette Guerin ( BCG ) .
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in ...
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024 - CG Oncology ( NASDAQ:CGON )
IRVINE, Calif., Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc.
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology ( SUO ) 25th Annual Meeting - CG Oncology ( NASDAQ:CGON )
IRVINE, Calif., Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc.
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sempra ( NYSE:SRE )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. analyst Scott Buck initiated coverage on WidePoint Corporation WYY with a Buy rating ...
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
IRVINE, Calif., Aug. 30, 2024 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc. ( NASDAQ: CGON ) , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, ...
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - CG Oncology ( NASDAQ:CGON )
IRVINE, Calif., Aug. 30, 2024 ( GLOBE NEWSWIRE ) -- CG Oncology, Inc.
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 -
Bladder Cancer Treatment Drug Market to Attain $14.24 billion by 2034, with 14.1% CAGR | Fact.MR Report
Rockville, MD., July 23, 2024 ( GLOBE NEWSWIRE ) -- According to a new report published by Fact.MR, the global Bladder Cancer Treatment Drug Market is estimated to reach a value of US$ 3.79 billion in 2024 and further expand at a CAGR of 14.1% from 2024 to 2034.
